cyanoVirin-n inhibits mannose-dependent
abStract Cyanovirin (CV-N) is a mannose-binding lectin that inhibits HIV-1 infection by blocking mannose-dependent target-cell entry via C-type lectins. Like HIV-1, Mycobacterium tuberculosis expresses mannosylated surface-structures and exploits C-type lectins to gain cell-access. Here we investigated whether CV-N, as for HIV-1, also inhibits M. tuberculosis infection. We found that CV-N specifically interacted with pathogenic mycobacteria by binding to the glycolipid lipoarabinomannan. Furthermore, CV-N competed with the C-type lectins DC-SIGN and mannose receptor for ligand binding and inhibited the binding of M. tuberculosis to dendritic cells but, unexpectedly, not to macrophages. Subsequent in vivo infection experiments in a mouse model demonstrated that CV-N, despite its activity, did not inhibit or delay M. tuberculosis infection. This outcome argues against a critical role for mannosedependent C-type lectin interactions during initial stages of murine M. tuberculosis infection and suggests that, depending on the circumstances, M. tuberculosis can productively infect cells using different modes of entry.
introduction Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the most deadly bacterial disease worldwide and kills ~1.7 million people each year. As the prevalence of drugresistant M. tuberculosis is rising and the current vaccine for TB, i.e. Mycobacterium bovis BCG, shows a variable efficacy (12) , new TB vaccines and drugs are urgently needed (40) . M. tuberculosis uses a large repertoire of strategies to modulate the host immune response, several of which are associated with mannosylated cell-surface structures (34) . Upon inhalation, M. tuberculosis enters the lungs and establishes an infection by invading alveolar macrophages (Mφ) and dendritic cells (DCs). For this, M. tuberculosis may use different receptors, including the mannose-binding C-type lectins macrophage mannose receptor (MMR) (29) and the dendritic cell-specific ICAM-3 Grabbing Non-Integrin (DC-SIGN) (32) . Both DC-SIGN and the MMR recognize mannosylated structures, including mycobacterial cell-surface glycolipids such as mannose-capped lipoarabinomannan (ManLAM) and phosphatidylinositol mannosides (PIMs) (Chapter 1 Figure 3 and Chapter 5 Figure 1 , respectively) (9, 14, 23, 33 ). Yet, the exact role of DC-SIGN and the MMR in establishing and maintaining M. tuberculosis infection remains unclear, as these receptors not only mediate mycobacterial phagocytosis, but also seem to have a role in modulating M. tuberculosisrelated immune pathology (10, 22, 34) .
Cyanovirin (CV-N) is a mannose-binding lectin derived from the cyanobacterium Nostoc ellipsosporum extensively studied for its ability to block infections with HIV-1 (8, 36, 41) . It does so by interacting with mannosylated HIV-1 gp120 and block targetcell entry via C-type lectins (2, 8). In addition, CV-N has been reported to reduce infectivity of the Ebola and Hepatitis C viruses, also by targeting surface-exposed mannosylated proteins (3, 16). As mentioned above, M. tuberculosis expresses a large number of mannosylated cell-surface structures which it may exploit to gain access to host immune cells (9, 14, 29, 34) . This suggests that CV-N, in analogy with its ability to block viral infections, may also abrogate infection with M. tuberculosis. Here we report our study investigating the ability of CV-N to inhibit M. tuberculosis infection. 
Cyanovirin-N
Recombinant CV-N was expressed in E. coli BL21(DE3) cells as described previously (5, 6). Cells were harvested by centrifugation (7500x g) and resuspended in 100 mL cold phosphate-buffered saline (PBS) (pH7.4) containing 10 mM benzamidine prior to lysis in a microfluidizer. The total cell lysate was centrifuged at 25,000x g, and the supernatant loaded directly onto a C18 cartridge from which CV-N was eluted with a step gradient from 0-80% CH 3 CN in H 2 O. Fractions containing CV-N (40-70% CH 3 CN) were combined, lyophilized, and purified by reverse-phase-HPLC yielding milligram quantities of CV-N with greater than 95% purity. These fractions were subjected to size-exclusion chromatography after reconstitution in PBS adjusted to pH7.4 with 0.5 M NaOH before loading onto a Superdex75 16/60 column. Fractions corresponding to homogeneous, monomeric CV-N were combined. The periodate method was used to conjugate horseradish peroxidase (HRP; Sigma) to CV-N (38, 39) . Before use, CV-N-HRP was dialyzed overnight (o/n) against H 2 O at 4°C.
SDS-PAGe/immunoblot
Bacterial cultures were grown until mid/late-log phase and disrupted with a Beadbeater (BioSpec). Supernatants were equalized for protein content using a BCA Protein Assay kit (Pierce). Cell lysates were run on a 12% SDS-PAGE gel in a tricine buffer (19) , followed by transfer on a polyvinylidene fluoride membrane (Millipore) (35) . Membranes were incubated in 1% bovine serum albumin (BSA) (Sigma) in PBS + 0.05% Tween-80 (PBST+BSA) followed by o/n incubations at room temperature (RT) with CV-N-HRP in PBST+BSA. After washing, membranes were developed using a mixture of 4-chloro-1-naphtol (Bio-Rad) and 3,3'-diaminobenzidine . 4HCl (Sigma-Aldrich).
CV-N-HrP adhesion assay
Man-and AraLAM, polyacrylamide (PAA)-linked glycoconjugates (0.1 µg per well) (18), or bacterial suspensions (A 600 =1; heat-killed at 85°C for 45 min) in NaCl-buffer were coated onto 96-well PVC-plates (BD Falcon, Biosciences) o/n at RT. ELISA-plates were washed with TSM-buffer containing 20 mM Tris-HCl (pH7.5), 150 mM NaCl, 1 mM MgCl 2 , 2 mM CaCl 2 and 0.05% Tween-80 (TSMT). TSM + 1% BSA (Fluka) was used as blocking buffer. CV-N-HRP was titrated starting from 2.5 µg mL -1 in TSM + BSA and left to incubate for 2h at RT. Binding of CV-N-HRP was detected using o-phenylenediamine dihydrochloride (OPD; Sigma-Aldrich) as coloring reagent and measuring absorption at 490 nm.
CV-N inhibition assay
Protocol as described above, but plates were now probed with serial dilutions of MMR-Fc (20) or a DC-SIGN-Fc construct (13) in absence or presence of 50 µg mL -1 CV-N for 2h at RT. Goat-anti-human IgG-PO (Jackson Laboratories) in 0.5% normal goat serum was used as secondary antibody.
Cells
Human peripheral blood mononuclear cells were isolated from buffy coats (Sanquin Bloodbank, Amsterdam, NL) by centrifugation on a Ficoll-Paque gradient (GE Healthcare), followed by selection for CD14+ monocytes using anti-CD14 magnetic beads and the Midi-MACS system (Miltenyi Biotech). Isolated monocytes were cultured in RPMI 1640 (Gibco) supplemented with 10% fetal calf serum (Gibco) (37°C, 5% CO 2 ) in presence of IL-4 (500 U mL -1 ) and GM-CSF (800 U mL -1 ) (PeproTech) to produce immature MoDCs (27) or in presence of 50 U mL -1 GM-CSF for MoMφ. For MoMφ, the culture medium was replenished with GM-CSF on day three after isolation (37) . Cells were used for further experiments on day 6 after isolation and tested for expression of DC-SIGN, MMR, and CD14 [MoDCs: DC-SIGN(high), MMR(high), CD14(low); MoMφ: DC-SIGN(low), MMR(high), CD14(high)].
MoDCs and MoMφ binding assays
M. tuberculosis mc 2 6020 cultures were grown until mid-log phase (A 600 =0.6-0.8), concentrated 10-fold in FITC-buffer (150 mM NaCl, 0.2 M Na 2 CO 3 (pH9.2), 0.05% Tween-80), and incubated with 250 μg mL -1 fluorescein isothiocyanate (FITC; SigmaAldrich) for 20 min at RT, after which the suspensions were washed and diluted in TSMT depending on the desired final multiplicity-of-infection (MOI). CV-N (or PBS) was added to the mycobacterial suspensions at a concentration of 200 μg mL -1 and incubated for 1h at RT. After this, the bacteria were washed and diluted in RPMI medium containing 10% (v/v) FCS, and fluorescence of the different suspensions was quantified using the FLUOstar-Galaxy microplate reader (BMG). Mycobacteria were added to MoDCs and MoMφ which were either 10 min pre-incubated with AZN-D1 (50 μg mL -1 ) (14) , or mannan (2 mg mL -1 ), respectively. After incubation for 45 min at 37ºC, the percentage of fluorescent cells was determined using a Flow Cytometer (C6, Accuri) and analyzed using manufacturer's software (CFlow Plus version 1.0.208.2).
Statistical analysis
In vitro cell binding studies: all values were expressed as means of at least three independent experiments (each carried out in triplicate) ± standard error of mean (n ≥ 3). The unpaired Student t test was used to identify significant differences between groups (p < 0.05).
In vivo experiments
M. tuberculosis H37Rv was grown to an A 650 of 0.4. Cells were harvested, resuspended in PBST, and filtered through a 5μm-filter to obtain a single-cell suspension (A 650 =0.67). Of this, 80 mL was added to 320 μL PBS supplemented or not with CV-N (100 and 500 mg mL -1 ; CV-N:mycobacteria ratio similar to pretreatment of MOI5-suspensions in the in vitro assays and five-fold higher, respectively). After 2h pre-incubation at RT, cells were diluted with 10 mL of PBST and used for aerosol infection of mice. Eight-weekold C57Bl/6 mice were infected with ~100 M. tuberculosis colony forming units (CFUs) using a BioAerosol nebulizing generator (CH Technologies Inc., Westwood, NJ) for 10 min. Mice from separate groups were euthanized at days 0, 7, 14 and 28. Organs (lungs, spleens and livers) were homogenized in 7H9 Middlebrook supplemented medium and dilutions plated on 7H11 Middlebrook agar plates supplemented with 10% OADC (7). The Animal Care and Use Committee (ACUC) of the National Institute of Allergy and Infectious Diseases, Division of Intramural Research, with permit number NIH IRP, PHS Assurance A4149-01, approved the animal study protocol LCID-3E under which all animal experiments were performed.
reSultS

CV-N specifically interacts with M. tuberculosis
To examine the ability of CV-N to interact with mycobacteria, four different mycobacterial species were coated onto 96 well-plates and probed with serial dilutions of HRP-coupled CV-N (CV-N+HRP). First, M. tuberculosis auxotrophic strain mc 2 6020 was tested, as well as the closely related vaccine strain M. bovis BCG strain Copenhagen, the fish-pathogen M. marinum strain E11, the non-pathogenic species M. smegmatis strain mc 2 155, and Escherichia coli strain DH5a as a control. In decreasing order of reactivity, CV-N bound M. tuberculosis > M. bovis BCG > M. marinum > M. smegmatis and E. coli ( Figure 1A ), demonstrating that CV-N binding was the highest for species belonging to the M. tuberculosis-complex. To investigate possible intra-species differences, CV-N-binding to a panel of different M. tuberculosis strains was also tested. As shown in Figure 1B , CV-N bound equally well to all four isolates suggesting that binding of CV-N was species rather than strain specific.
ManLAM is the primary CV-N ligand
Next we investigated which mycobacterial structures were recognized by CV-N. It has been reported that CV-N recognizes a(1,2)-linked mannosyl residues (5, 6), which are also present in the mannose cap of ManLAM, and in the phosphatidylinositol hexamannoside PIM 6 (Chapter 1 Figure 3 and Chapter 5 Figure 1, respectively) . First, total cell lysates of M. tuberculosis mc 2 6020, M. bovis BCG Copenhagen, M. marinum E11, and M. smegmatis mc 2 155 were examined on SDS-PAGE/immunoblot with CV-N+HRP. Staining was observed at the position of ManLAM for M. tuberculosis, M. bovis BCG, and M. marinum, but not for M. smegmatis which is known to express a phosphatidylinositol-capped version of LAM (PILAM) (Figure 2A and S1A). In addition, CV-N staining at the position of PIM 6 was observed in all four species although with varying intensity (Figure 2A and S1A) .
To obtain further evidence that ManLAM and PIM 6 were indeed CV-N ligands, lysates prepared from wild-type M. bovis BCG and isogenic mutant strains with specific defects in ManLAM and/or PIM 6 biosynthesis were subjected to SDS-PAGE/ immunoblot and probed with CV-N+HRP. As shown in Figure S1B , the mutant strains, as compared to wild-type M. bovis BCG, showed a different immunoblot profile. In case of the M. bovis BCG DcapA strain, which expresses LAM devoid of mannose caps (1), staining at the position of LAM was no longer visible ( Figure S1B ). On the other hand, probing a M. bovis BCG DpimE mutant, which synthesizes PIM 2 and PIM 4 , but not PIM 6 (9), demonstrated that the reactivity at the position of PIM 6 was absent. Finally, with the DcapADpimE double mutant strain, which misses both ManLAM and PIM 6 , staining for both structures was absent ( Figure S1B ). To gain insight into the relative contribution of ManLAM and PIM 6 for binding of CV-N, the wild-type and mutant M. bovis BCG strains were analyzed for CV-N binding by whole-cell ELISA. As shown in Figure 2B , mutation of either pimE or capA led to a reduction in CV-N binding whereas binding to the DcapADpimE double mutant was almost absent. However, when compared to each other, the abrogating effect of the capA mutation was much stronger than the mutation in pimE, suggesting that the mannose caps on ManLAM are the dominant CV-N ligands. This finding is consistent with our earlier observation that M. smegmatis, which is devoid of ManLAM but does express PIM 6 , shows minimal CV-N binding ( Figure 1A) .
binding of CV-N to ManLAM is dependent on the length of the mannose cap
The mannose caps of ManLAM contain one to three mannosyl residues. To investigate the influence of mannose cap length on CV-N binding, a range of polyacrylamide (PAA)-coupled glycoconjugates resembling the LAM-mannose cap structures were probed with CV-N+HRP. Glycoconjugates (man) 1 ara-PAA, (man) 2 ara-PAA and (man) 3 ara-PAA are equivalent for short to long mannose caps on ManLAM respectively, and the structure of (ara) 6 -PAA is equivalent to the uncapped Ara 6 motif found in LAM (18) . As shown in Figure 2C , CV-N recognized both (man) 2 ara-PAA and (man) 3 ara-PAA, while the single mannose-structure (man) 1 ara-PAA and the hexa-arabinose motif were not bound ( Figure 2C ). In a similar assay, ManLAM and non-capped LAM (AraLAM) were also tested. Consistent with the data for the glycoconjugates, CV-N recognized ManLAM but not AraLAM ( Figure 2D) . Hence, the presence of at least a dimannoside cap is essential for recognition by CV-N.
CV-N inhibits the binding of MMr-Fc and DC-SIGN-Fc to ManLAM and M. tuberculosis
ManLAM is a ligand for the human C-type lectins DC-SIGN and the MMR (14, 18, 30) . To test whether CV-N can compete with DC-SIGN and the MMR for ligand binding, glycoconjugate (man) 3 ara-PAA, purified ManLAM, or whole M. tuberculosis cells were coated onto a 96-well plate and probed with a DC-SIGN-Fc or MMR-Fc construct in the presence or absence of CV-N. Binding of both DC-SIGN-Fc and MMR-Fc to the coating was inhibited by CV-N ( Figure 3A and 3B) . Binding of the highest concentration of DC-SIGN-Fc to (man) 3 ara-PAA, ManLAM, and M. tuberculosis, was reduced by CV-N by 68±17% (mean±SEM), 71±16%, and 44±6%, respectively ( Figure  3A) . Similarly, binding of MMR-Fc to (man) 3 ara-PAA, ManLAM, and M. tuberculosis was reduced by CV-N by 86±1%, 87±3%, and 87±5%, respectively ( Figure 3B ).
CV-N inhibits binding of M. tuberculosis to DCs but not to macrophages
As the MMR is an important receptor for mycobacteria on Mφ (29), and DC-SIGN the major receptor for mycobacteria on DCs (32), our next goal was to investigate whether CV-N was also able to block binding of M. tuberculosis to intact Mφ and DCs. Fluorescently labeled mycobacteria were pre-incubated with CV-N or PBS, after which the mycobacteria were washed to remove free CV-N and added to human monocyte-derived (Mo)Mφ or MoDCs. Binding of M. tuberculosis was monitored by flow cytometry. While pre-treatment with CV-N reduced binding of M. tuberculosis to MoDCs by ~40% ( Figure 3C ), no significant inhibition was observed for binding to the Figure 3D ), albeit expressing significant amounts of MMR (data not shown). To determine whether the binding of M. tuberculosis to MoMφ was indeed mannose independent, an excess of mannan was added extracellularly. As shown in Figure 3D , addition of mannan did not reduce the binding of M. tuberculosis to the macrophages, indicating that other, mannose-independent receptors mediated M. tuberculosis binding in our assay system. Conversely, binding of CV-N pre-treated M. tuberculosis to MoDCs could still be further blocked by a DC-SIGN-blocking antibody (AZN-D1) reaching the same level as with inhibition by AZN-D1 of bacteria that were not preincubated with CV-N (≈8%). Hence, CV-N appears to specifically inhibit binding of M. tuberculosis to DC-SIGN on MoDCs.
MoMφ (
CV-N does not inhibit M. tuberculosis-infection in a murine aerosol infection model
As CV-N is able to inhibit interaction of M. tuberculosis with DC-SIGN(-Fc) and MMR-Fc, the effect of CV-N on M. tuberculosis infection was next examined in vivo. Although CV-N failed to block the interaction of M. tuberculosis with human MoMφ in vitro, the uptake route of M. tuberculosis in the murine lung may be different. Hence, mice were infected with ~100 CFUs of M. tuberculosis H37Rv pre-incubated or not with CV-N using a validated aerosol infection model (7). Mice were sacrificed at days 0, 7, 14 and 28 and CFUs were enumerated in the lungs, spleen and liver. As shown in Figure 4 , no differences in CFU counts were observed between mice infected with untreated or CV-N-pre-treated M. tuberculosis. Also when a higher infection dose was applied (≈10-fold higher), no significant differences in infection with CV-N-treated or untreated bacteria were observed ( Figure S2 ). In conclusion, at least in this model system, CV-N pre-coating of M. tuberculosis did not delay or alter the outcome of infection.
diScuSSion
Mannosylated mycobacterial cell-surface structures have been associated with various immunomodulating properties of mycobacteria (21, 34) . Binding of these structures to host C-type lectins, including DC-SIGN and MMR, has been suggested to modulate the host immune response and to assist in establishing M. tuberculosis infection (10, 14, 17, 26, 29, 30, 32, 34) . In this study, we demonstrate that CV-N, a mannose-binding lectin, specifically interacts with M. tuberculosis and reduces the interaction with host mannose-binding C-type lectins but that this inhibition does not alter the outcome of infection.
First, we tested the ability of CV-N to interact with different mycobacterial species. Interestingly, CV-N displayed enhanced binding to M. tuberculosis as compared to the vaccine strain M. bovis BCG and the fish-pathogen M. marinum, whereas it showed only marginal binding to non-pathogenic M. smegmatis ( Figure 1A) . This indicates a possible relationship between pathogenicity and/or host specificity of different species and the presence of surface-exposed mannosyl residues. Yet, this relationship is not absolute, as CV-N also efficiently bound to the avirulent M. tuberculosis strain H37Ra ( Figure 1B) .
The observed binding pattern of CV-N shows similarity to that of host-cell receptors DC-SIGN and MMR (9, 18, 30, 33): CV-N recognized the a(1,2)-linked mannosyl residues in PIM 6 and in the mannose cap of ManLAM, but not the a(1,2)-linked mannosyl side branches present on the mannan core domain of LAM/LM or the less mannosylated PIMs PIM 4 and PIM 2 in which a(1,2)-linked mannosyl residues are missing (Figure 2 and S1 ). However, some differences between the binding patterns of DC-SIGN/MMR and CV-N may also exist: the MMR has been demonstrated to be a phagocytic uptake receptor on MoMφ for virulent M. tuberculosis strains H37Rv and Erdman, but not for strain H37Ra (29), while CV-N, at least in our assay system, did not discriminate between these two strains ( Figure 1B) . Furthermore, genetically uncapping LAM by mutating capA in combination with the absence of PIM 6 (pimEmutation) almost completely abrogated CV-N binding ( Figure 2B ). In contrast, the same set of mutations was previously reported not to disturb the binding of DC-SIGN to M. bovis BCG (1, 9). The reason for this discrepancy is unclear, but may be related to differences in specificity. Figure 3D ). In contrast to DCs, for which DC-SIGN is the dominant receptor for binding of mycobacteria (32) , Mφ express several receptors all of which are reported to bind mycobacteria (11) . Therefore, binding of M. tuberculosis to the MoMφ was probably mediated by receptors that do not depend on the recognition of mannosyl residues, e.g. complement receptors (29). Of note, as M. tuberculosis induces DC-SIGN expression in human alveolar Mφ (31), uptake by these cells in humans may still be inhibited by CV-N.
The effect of CV-N surface-coating on M. tuberculosis infection in vivo was tested in a murine aerosol infection model. Results from two independent experiments ( Figure  4 and S2), revealed that CV-N, although capable of inhibiting mannose-dependent M. tuberculosis-C-type lectin interactions, did not block or delay the infection. As CV-N is known to be active also in vivo, this suggests that mannose-dependent interactions, in this model system, were (at least partially) dispensable during the early stages of infection. This finding is consistent with earlier reports in which it was demonstrated that mutants defective in producing mannose caps on LAM and/or unable to produce PIM 6 behave similar to wild-type strains both in vitro and in vivo (1, 9). Whether this finding is specific for the murine infection model or is also true in other models, most importantly humans, remains to be seen. Possibly, a protective effect by CV-N cannot be observed in this model system as the murine C-type lectins differ too much from the human versions, in particular DC-SIGN (24). Furthermore, CV-N did not fully block Mycobacterium-C-type lectin interactions leaving open the possibility that the residual binding, possibly via capsular a-glucan, was enough to support cell-entry via mannose-binding C-type lectins.
In conclusion, we demonstrated here that coating mycobacterial mannosylated surface structures with an exogenous compound other than antibodies abrogates mannose-dependent Mycobacterium-C-type lectin interactions. This makes CV-N, and CV-N-like molecules, an interesting class of compounds. However, as demonstrated in the in vivo infection experiments, inhibition of these mannose-dependent interactions did not alter the outcome of infection. This finding suggests that mannose-dependent interactions are, at least partially, dispensable during the early phases of infection. Important remaining questions are then what are the preferred routes for M. tuberculosis host-cell entry in vivo and more importantly, does entry via different routes lead to different outcomes of infection? Further addressing these issues will not only answer the important question whether or not targeting mycobacterial cell-surface structures, for instance through carbohydrate-based antibody vaccines, and thereby altering the cellular uptake route can be used to combat M. tuberculosis, but may also provide further insight into the mechanisms explaining the success of M. tuberculosis as a very potent human adversary. (low dose CV-N), and 3.65 . 10 6 CFU mL -1 (high dose CV-N) aerosolic solution of mycobacteria on day 0. CFUs were counted in (A) lung, and (B) spleen. Shown is median of five mice per group plus standard deviation.
